Phase I/II study of triweekly administration regimen of irinotecan and TS-1 in patients with advanced colorectal cancer
Phase 1
- Conditions
- advanced colorectal cancer
- Registration Number
- JPRN-UMIN000001365
- Lead Sponsor
- Kyushu Medical Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Massive pleural effusion or massive ascites (2) Symptomatic brain metastases (3) Active diarrhea
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) Phase I To determine the recommended dose 2) Phase II Response Rate
- Secondary Outcome Measures
Name Time Method Safety, Overall survival, Progression free survival